Tonix Pharmaceuticals announced that EVERSANA has been selected to support the launch strategy and commercial planning of Tonmya in the U.S. Specifically, EVERSANA will work with Tonix to assess the fibromyalgia landscape and help plan an efficient go-to-market strategy. “EVERSANA shares our commitment to delivering novel therapeutics to patients in need,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “We are excited to further refine our business strategy for the anticipated launch of Tonmya in 2025. It has been over a decade since patients suffering with fibromyalgia have been provided a new therapeutic option.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TNXP:
- Tonix Pharma Advances with Promising TNX-1500 Studies
- Tonix Pharmaceuticals Announces Translation of Preclinical Pharmacokinetic Parameters of TNX-1500 (Fc-modified humanized anti-CD40L mAb) Supports Monthly i.v. Dosing in Humans
- Tonix Pharma Advances TNX-1500 Trial, Cautions Investors
- Tonix Pharmaceuticals completes clinical stage of Phase 1 trial for TNX-1500
- Tonix Pharma Expands Asian Market Reach with Tonmya™ Study
